Home › Therapeutic areas › Oncology › Endometrial Cancer
Endometrial Cancer (8 companies)
Companies with an active program in Endometrial Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 2 | Phase 2 | $61.4M | 9 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.36B | 9 |
| AVBP | ArriVent BioPharma | Oncology | 1 | Phase 3 | $553M | 7 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $109M | 15 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | $191M | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $507M | 10 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $92.2M | 7 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $1.78B | 12 |
No companies match.